Amicus Therapeutics Inc
FOLD14.180USD
+3.290+30.21%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
4.37BMarket Cap
LossP/E TTM
More Details of Amicus Therapeutics Inc Company
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Amicus Therapeutics Inc Info
Ticker SymbolFOLD
Company nameAmicus Therapeutics Inc
IPO dateMay 31, 2007
CEOCampbell (Bradley Lewis)
Number of employees499
Security typeOrdinary Share
Fiscal year-endMay 31
Address47 Hulfish Street
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08542
Phone16096622000
Websitehttps://www.amicusrx.com/
Ticker SymbolFOLD
IPO dateMay 31, 2007
CEOCampbell (Bradley Lewis)
Company Executives of Amicus Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Bradley Lewis Campbell
Mr. Bradley Lewis Campbell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
615.74K
--
Ms. Ellen S. Rosenberg, J.D.
Ms. Ellen S. Rosenberg, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
263.90K
--
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Independent Director
Independent Director
142.56K
+16.71%
Mr. Burke W. Whitman
Mr. Burke W. Whitman
Independent Director
Independent Director
118.60K
+20.79%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
115.86K
+21.39%
Mr. Craig A. Wheeler
Mr. Craig A. Wheeler
Independent Director
Independent Director
84.63K
+31.79%
Dr. Adm. Eiry Wyn Roberts, M.D.
Dr. Adm. Eiry Wyn Roberts, M.D.
Independent Director
Independent Director
76.28K
+36.54%
Ms. Lynn Dorsey Bleil
Ms. Lynn Dorsey Bleil
Independent Director
Independent Director
58.62K
+53.43%
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Director
Independent Director
51.41K
+65.85%
Mr. David M. Clark
Mr. David M. Clark
Chief People Officer
Chief People Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Bradley Lewis Campbell
Mr. Bradley Lewis Campbell
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
615.74K
--
Ms. Ellen S. Rosenberg, J.D.
Ms. Ellen S. Rosenberg, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
263.90K
--
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Independent Director
Independent Director
142.56K
+16.71%
Mr. Burke W. Whitman
Mr. Burke W. Whitman
Independent Director
Independent Director
118.60K
+20.79%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
Independent Chairman of the Board
Independent Chairman of the Board
115.86K
+21.39%
Mr. Craig A. Wheeler
Mr. Craig A. Wheeler
Independent Director
Independent Director
84.63K
+31.79%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Ex U.S
90.36M
58.41%
U.S
64.33M
41.59%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.01%
Wellington Management Company, LLP
9.28%
BlackRock Institutional Trust Company, N.A.
6.98%
William Blair Investment Management, LLC
5.10%
Avoro Capital Advisors LLC
4.87%
Other
63.76%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.01%
Wellington Management Company, LLP
9.28%
BlackRock Institutional Trust Company, N.A.
6.98%
William Blair Investment Management, LLC
5.10%
Avoro Capital Advisors LLC
4.87%
Other
63.76%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
41.09%
Investment Advisor
33.25%
Hedge Fund
21.43%
Research Firm
3.27%
Private Equity
2.60%
Sovereign Wealth Fund
1.05%
Individual Investor
0.69%
Pension Fund
0.56%
Venture Capital
0.42%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
537
321.41M
109.22%
--
2025Q3
556
321.74M
110.12%
-1.09M
2025Q2
564
322.79M
109.37%
+6.32M
2025Q1
560
316.34M
106.26%
-10.87M
2024Q4
551
308.77M
110.93%
-5.22M
2024Q3
542
313.95M
115.49%
-6.33M
2024Q2
530
319.14M
116.65%
-6.57M
2024Q1
522
326.28M
115.37%
-15.39M
2023Q4
515
323.40M
109.55%
+19.41M
2023Q3
512
304.11M
113.70%
-8.58M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
29.35M
9.52%
+349.65K
+1.21%
Jun 30, 2025
Wellington Management Company, LLP
29.12M
9.45%
-76.66K
-0.26%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
21.92M
7.11%
-1.00M
-4.37%
Jun 30, 2025
William Blair Investment Management, LLC
14.64M
4.75%
-136.49K
-0.92%
Jun 30, 2025
Avoro Capital Advisors LLC
18.00M
5.84%
-2.50M
-12.20%
Jun 30, 2025
Millennium Management LLC
7.42M
2.41%
+4.06M
+120.92%
Jun 30, 2025
State Street Investment Management (US)
11.57M
3.75%
+2.05M
+21.53%
Jun 30, 2025
Vestal Point Capital, LP
11.90M
3.86%
+7.63M
+178.36%
Jun 30, 2025
Citadel Advisors LLC
5.97M
1.94%
-1.86M
-23.79%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Products ETF
2.34%
WisdomTree BioRevolution Fund
1.54%
ALPS Medical Breakthroughs ETF
1.16%
First Trust Innovation Leaders ETF
0.98%
State Street SPDR S&P Biotech ETF
0.84%
VictoryShares Small Cap Free Cash Flow ETF
0.67%
Invesco NASDAQ Future Gen 200 ETF
0.64%
Direxion Daily S&P Biotech Bull 3X Shares
0.51%
First Trust Multi-Manager Small Cap Opportunities ETF
0.49%
JPMorgan Fundamental Data Science Small Core ETF
0.42%
View more
Virtus LifeSci Biotech Products ETF
Proportion2.34%
WisdomTree BioRevolution Fund
Proportion1.54%
ALPS Medical Breakthroughs ETF
Proportion1.16%
First Trust Innovation Leaders ETF
Proportion0.98%
State Street SPDR S&P Biotech ETF
Proportion0.84%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.67%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.64%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.51%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.49%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.42%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Amicus Therapeutics Inc?
The top five shareholders of Amicus Therapeutics Inc are:
The Vanguard Group, Inc. holds 29.35M shares, accounting for 9.52% of the total shares.
Wellington Management Company, LLP holds 29.12M shares, accounting for 9.45% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 21.92M shares, accounting for 7.11% of the total shares.
William Blair Investment Management, LLC holds 14.64M shares, accounting for 4.75% of the total shares.
Avoro Capital Advisors LLC holds 18.00M shares, accounting for 5.84% of the total shares.
The Vanguard Group, Inc. holds 29.35M shares, accounting for 9.52% of the total shares.
Wellington Management Company, LLP holds 29.12M shares, accounting for 9.45% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 21.92M shares, accounting for 7.11% of the total shares.
William Blair Investment Management, LLC holds 14.64M shares, accounting for 4.75% of the total shares.
Avoro Capital Advisors LLC holds 18.00M shares, accounting for 5.84% of the total shares.
What are the top three shareholder types of Amicus Therapeutics Inc?
The top three shareholder types of Amicus Therapeutics Inc are:
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Amicus Therapeutics Inc (FOLD)?
As of 2025Q4, 537 institutions hold shares of Amicus Therapeutics Inc, with a combined market value of approximately 321.41M, accounting for 109.22% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.91%.
What is the biggest source of revenue for Amicus Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Amicus Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
